judgment. They assume only that it is often difficult if not impossible to distinguish cases in which financial gain does have improper influence from those it which it does not." (8) The NEJM has now sought to reinterpret and downplay the importance of conflicts of interest in medicine by publishing articles that show little understanding of the meaning of the term. The concern is not whether physicians and researchers who receive industry money have been bought by the drug companies, as Drazen writes, (4) or whether members of guideline panels or advisory committees to the US Food and Drug Administration with ties to industry make recommendations that are motivated by a desire for financial gain, as Rosenbaum writes. (1) (3) The essential issue is that it is impossible for editors and readers to know one way or the other. (6) (7) Judges are expected to recuse themselves from hearing a case in which there are concerns that they could benefit financially from the outcome. Journalists are expected not to write stories on topics in which they have a financial conflict of interest. The problem, obviously, is that their objectivity might be compromised, either consciously or unconsciously, and there would be no easy way to know whether it had been. Yet Rosenbaum and Drazen seem to think it is insulting to physicians and medical researchers to suggest that their judgment can be affected in the same way. Doctors might wish it were otherwise, but none of us is immune to human nature.
Straw men
Rosenbaum's language is colorful, but her arguments for the purported harms of conflict of interest policies and regulations are fanciful and data-free. No one is proposing that "we prevent the dissemination of expertise, thwart productive collaborations, or dissuade patients from taking effective drugs," or allow "true experts to be replacedon advisory panels, as authors of reviews and commentaries, in other capacities of authorityby people whose key asset is being conflict-free." (3) Where is the evidence of "a loud chorus of shaming," (2) or "a stifling of honest discourse," (2) or that "the license to trample the credibility of physicians with industry ties has silenced debate?" (3) Silliness and fear mongering about straw men are masquerading as scholarly analysis.
In 2014, under the Open Payments program (the Physician Payment Sunshine Act which is part of the Affordable Care Act), the Centers for Medicare and Medicaid Services in the United States published 4.45 million financial transactions from healthcare industries to physicians and teaching hospitals over just the last five months of 2013; the total value was nearly $3.7bn (£2.4bn; €3.4bn). (9) When full data for 2014 are reported later in 2015, the amounts may well exceed $9bn. Drug and device companies are investor owned businesses that are required to maximize profits by any legal means. These companies are not charities, so they expect to get something in return for all the largesse; the evidence is that they do, and it is naive to explain the situation otherwise.
Put simply, financial conflicts of interest in medicine are not beneficial, despite strained attempts to justify them and to make a virtue of self interest. Unmistakably, collaborations between academia and industry can speed medical progress and benefit patients. Such partnerships, however, can flourish with far less money in aggregate flowing from drug and device manufacturers to physicians and their institutions, and without the web of other lucrative ties between industry and physicians that lack a clear scientific or medical purpose.
There are few reasons for physicians and other investigators to have financial associations with industry other than research support and bona fide consulting related to specific research programs and projects. Physicians who develop products and hold patents or receive royalties should not evaluate the product. Other types of payments, such as speakers' and other personal fees, payments to be ghost authors of review articles, and ill defined consulting arrangements, distort physicians' work and undermine our independence, as has been repeatedly documented. And there are no excuses for outright gifts, such as meals, travel, lodging expenses, and entertainment.
Editorial responsibility
In 1984, the late Arnold S Relman, then the NEJM's editor in chief, instituted the first conflict of interest policy at any major medical journal. (10) The policy required authors of research papers to disclose all financial ties they had to health industries, and if the ties were deemed significant they were published. In 1990, Relman extended the policy to prohibit authors of editorials and review articles from having any financial interest in a company (or its competitor) that was discussed in the article, since these types of manuscripts do not contain primary data but rely exclusively on the authors' judgment in citing and interpreting the literature. (11) As Relman's successors, two of us (JPK and MA) continued these policies.
We found that it was sometimes difficult, but nearly always possible, to find outstanding authors with the needed expertise and without a conflict of interest to write editorials and review articles. (12) In 2002, however, after Drazen succeeded Angell, the policy was weakened, so that it only applied to authors with "any significant financial interest in a company (or its competitor) that makes a product discussed in the article." (13) To its credit,
The BMJ has taken the opposite approach and implemented a zero tolerance policy on educational articles by authors with industry ties. (14) The privilege to serve as an editor of a major medical journal is accompanied by the responsibility to provide leadership on the critical issues that define the profession. How medicine responds to conflicts of interest and earns the trust of the larger society in which we exist is one such issue. In 1990, it was a bad idea for authors of editorials, review articles, and other opinion articles in medical journals to have financial conflicts of interest. A quarter of a century later, it is a very bad idea. The articles by Rosenbaum and the supportive editorial by
Drazen could presage a further weakening of the conflict of interest policy at the NEJM, or they could serve as a wake-up call for all medical journals and the profession. It is time to move forward, not backward.
Pull quotes: Doctors might wish it were otherwise, but none of us is immune to human nature Financial conflicts of interest in medicine are not beneficial, despite strained attempts to justify them and to make a virtue of self interest
Competing interests: We have read and understood BMJ policy on declaration of interests and declare RS was deputy editor and national correspondent at NEJM and is now editor at large and viewpoints editor at JAMA Internal Medicine. JPK and MA were both editors in chief of NEJM.
